肝癌影像学进展综述
本综述总结肝癌影像学在超声、CT、MRI及PET示踪剂等方面的技术创新,比较LI-RADS、EASL等指南体系对HCC诊断标准的异同,并探讨基于影像的HCC预后分层及iCCA亚型鉴别,最后讨论影像组学与人工智能的验证挑战。
要点
- 影像学贯穿肝癌全程管理,从监测、早诊到分期、预后分层及疗效评估。
- HCC诊断指南在血管征象、肝胆期及Kupffer期超声标准上存在差异。
- 影像特征可反映HCC生物学表型(如增殖类、MTM亚型、MVI风险)并指导治疗分配。
核心结论
- 肝癌影像学已从检测工具演变为生物学表征与个体化治疗指导的综合平台。
研究设计与样本
- 综述类文章,检索范围未在摘要中明确报告。
主要发现
- 超声、多期及光谱CT、肝胆对比剂MRI、简化MRI协议和FAPI等PET示踪剂取得技术进展。
- LI-RADS、EASL、AASLD、KLCA-NCC和APASL等HCC诊断指南在血管征象、肝胆期解读和Kupffer期超声标准上存在融合与差异。
- HCC与iCCA存在生物学连续谱,影像特征可反映该表型谱。
- 基于影像的HCC预后分层可捕获增殖类、巨梁状-massive亚型、微血管侵犯可能性、免疫微环境特征及VETC表型。
- 定量影像和超声造影灌注可鉴别iCCA小胆管型与大管管型,并预测富间质侵袭性变异。
关键数值与推荐
- HCC诊断指南体系包括LI-RADS、EASL、AASLD、KLCA-NCC和APASL,重点涉及血管征象、肝胆期解读及Kupffer期超声标准。
- iCCA影像进展可区分小胆管型与大管管型亚型,并预测富间质侵袭性变异。
临床怎么用
- 临床可利用影像特征评估HCC生物学表型,辅助治疗分配决策,超越仅依赖肿瘤大小和数目。
- 在iCCA中可应用定量影像和超声造影灌注鉴别亚型并预测侵袭性变异。
- 疗效评估需关注局部治疗和免疫治疗反应评估标准的挑战。
局限性
- 摘要未明确报告综述的检索范围及纳入文献数量。
- 影像组学与人工智能的当前验证挑战在摘要中仅提及,未展开具体内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liver cancer remains a major global health burden, with hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) accounting for the vast majority of primary liver malignancies. As most patients are diagnosed at advanced stages, imaging plays a central role across the entire care continuum - from surveillance and early detection to diagnosis, staging, prognostic stratification, and treatment response assessment. Recent advances in imaging technology, diagnostic frameworks, and computational analysis have substantially expanded the clinical value of liver imaging. This review summarises key developments in liver cancer imaging, beginning with technical innovations in ultrasound, multiphasic and spectral CT, MRI with hepatobiliary contrast agents, abbreviated MRI protocols, and evolving PET tracers such as FAPI. We then examine the convergence and remaining differences among major diagnostic guideline systems for HCC, including LI-RADS, EASL, AASLD, KLCA-NCC, and APASL, with emphasis on vascular hallmarks, hepatobiliary phase interpretation, and Kupffer-phase contrast-enhanced ultrasound criteria. We also discuss the concept of the HCC-iCCA biological continuum, and how imaging features can reflect this phenotypic spectrum. A major focus is the emerging concept of imaging-based prognostication of HCC, which captures biologically meaningful phenotypes such as proliferative class, macrotrabecular-massive subtype, microvascular invasion likelihood, immune microenvironment signatures, and VETC phenotype. We discuss how these imaging features reflect underlying molecular programmes and may inform treatment allocation beyond tumour size and number. In iCCA, advances in quantitative imaging and contrast-enhanced ultrasound perfusion enable differentiation of small-duct vs. large-duct subtypes and prediction of stromal-rich aggressive variants. Treatment response assessment criteria are reviewed, addressing challenges in evaluating locoregional therapies and immunotherapy. Finally, we examine the emerging roles of radiomics and artificial intelligence, focusing on current validation challenges. Together, these advances demonstrate the evolution of liver cancer imaging from a detection tool to a comprehensive platform for biological characterisation and personalised treatment guidance.
引用
- Joo I, Lee JM, Ronot M, et al. Advances in the imaging of liver cancer. J Hepatol. 2026. PMID: 42744522. doi:10.1016/j.jhep.2026.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。